Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16324142 | 0.98 | MKNK1 (0.51) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL22510132 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL477032 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL3243144 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL84692 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL19493139 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL5494796 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL4323183 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL29893844 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7DGAT1LRRK2 | |
| SCHEMBL454803 | 0.73 | TGFBR1 (0.48) | MKNK1DYRK1AKLK7SSTR4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2026-04-02 | — | — | US | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250326757-A1 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2025-10-23 | — | — | US | disclosed |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | ASTRAZENECA AB (SE) | 2025-10-21 | — | — | US | disclosed |
| WO-2025125575-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | WO | disclosed |
| US-20250197411-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| EP-4532499-A1 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | Astrazeneca AB (SE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119137125-A | Solid forms of heterocyclylamides as 1RAK4 inhibitors | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2010068452-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7306631-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1732509-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | The Procter and Gamble Company (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| WO-2005097052-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-20 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | MKNK1 3898/4885DYRK1A 2772/4885KLK7 1959/4885 |
| US-20250326757-A1 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK3 | MKNK1 505/4885DYRK1A 1098/4885KLK7 3472/4885 |
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK3, IRAK4, IRAK2 | MKNK1 843/4885DYRK1A 1549/4885KLK7 4424/4885 |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | IRAK4, IRAK1, IRAK2 | MKNK1 647/4885DYRK1A 1487/4885KLK7 2996/4885 |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | MKNK1 3898/4885DYRK1A 2772/4885KLK7 1959/4885 |
| US-20250197411-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | MKNK1 499/4885DYRK1A 3479/4885KLK7 3766/4885 |
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | MKNK1 532/4885DYRK1A 3386/4885KLK7 3883/4885 |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, JUP | MKNK1 704/4885DYRK1A 2166/4885KLK7 204/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | MKNK1 3957/4885DYRK1A 2755/4885KLK7 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.